Europe Biosimilars Market Examined in New Kuick Research Report Available at

19 Nov 2015 • by Natalie Aster

LONDON – Biosimilars have come forth as novel modality having lower price with similar therapeutic efficacy such as biologics. They are introduced in the market after the patent expiration of biologics, and Europe became the first market to allow commercialisation of biosimilars. The European Commission enacted legislation in 2004 creating an approval pathway for biosimilars. Since the first biosimilar was approved by the European Medicines Agency in 2006, a number of biosimilars have been introduced in the European market due to higher cost arbitrage and applicability in manifold indications. In such a manner, European countries are anticipated to ease the burden from their healthcare system using biosimilars.

Biosimilars have been introduced for a range of diseases offering plethora of options to the patients. Supportive cancer treatments have a huge consumer base owing to which respective biosimilars are increasingly in demand. Erythropoietin and Filgrastim biosimilars are widely used in the European market; these well-established segments have numbers of products in comparison with other categories of diseases. Biosimilar monoclonal antibodies are in great demand due to their high level of efficacy and safety, minimised side effectsm as well as lower cost as against biologic monoclonal antibodies. Apart from this, the market has also seen the introduction of biosimilar insulin, which has created a novel segment owing to which more biosimilar products will likely come into the market in the offing.

New cutting-edge report “Europe Biosimilars Market Opportunity Outlook 2020” developed by Kuick Research examines the biosimilars marketplace in Europe, providing an in-depth analysis of key trends across the major countries in the region. The study gives information on the introduction of biosimilars in the European market by segment; reviews the risk management planning and safety regulation scenario; analyses the market dynamics; gives a granular mapping of the regulatory framework; offers a clinical and non-clinical guideline for the development of biosimilars in the European region. The study casts light on biosimilar pipeline by company, country, phase and indication; presents clinical insights into the biosimilars that are currently marketed in Europe; covers suspended and discontinued biosimilars. An all-round review of the competitive landscape alongside company profiles can also be found in the report.

Report Details:

Europe Biosimilars Market Opportunity Outlook 2020
Published: November, 2015
Pages: 310
Price: US$ 2,400.00 

More new studies by the publisher can be found at Kuick Research page


The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970